Entrepreneurs Fund

General Fusion Inc., established in 2002 and headquartered in Burnaby, Canada, specializes in developing commercial Magnetized Target Fusion (MTF), a hybrid fusion method combining magnetic confinement and inertial confinement principles. The company focuses on creating utility-scale fusion power using its patent-pending MTF concept, which has the potential to provide clean, safe, and economical energy. General Fusion develops key subsystems such as plasma injectors, acoustic drivers, and liquid metal vortex compression tests to advance its MTF technology. Backed by a global syndicate of investors, industry leaders, and technology pioneers, General Fusion aims to demonstrate and commercialize its innovative fusion power plants by the end of the decade.

Realeyes is a pioneering company specializing in computer vision and emotion AI. It helps businesses enhance customer experiences and drive growth by measuring human responses to video content at scale and speed. Using webcams and advanced machine learning techniques, Realeyes' platform analyzes facial expressions to quantify emotional reactions, enabling clients like Mars Inc., P&G, and Netflix to create targeted, optimized content. Over 200 leading brands and media companies rely on Realeyes for these insights.

OptiNose, Inc., established in 2010 and headquartered in Yardley, Pennsylvania, is a specialty pharmaceutical company specializing in nasal drug delivery technologies and therapies. The company's proprietary Bi-Directional Delivery system enables more efficient drug deposition in the upper posterior regions of the nasal cavity, unlike traditional devices. OptiNose's flagship product, XHANCE, utilizes this technology to deliver a topically-acting corticosteroid for treating chronic rhinosinusitis with and without nasal polyps. The company is also developing OPN-300 for rare genetic obesity and autism spectrum disorder treatments, and has licensing agreements for Onzetra Xsail and orexin receptor-related products. OptiNose has offices in Norway and the UK, focusing on improving drug delivery, onset of action, efficacy, and reducing side effects.

Vasopharm GmbH is a biopharmaceutical company based in Wurzburg, Germany, specializing in the discovery and development of therapeutics for cerebro- and cardiovascular diseases. Founded in 1998, Vasopharm focuses on addressing acute niche indications with significant unmet medical needs. The company's therapeutic pipeline features VAS203, an allosteric nitric oxide synthase inhibitor designed to reduce excessive nitric oxide production in cerebral vessels, thereby preventing dangerous increases in intracranial pressure and mitigating inflammatory responses following traumatic brain injury. Additionally, Vasopharm is developing VAS2870, a modulator of NAD(P)H oxidase, aimed at treating peripheral arterial occlusive diseases. Through its innovative approaches, Vasopharm seeks to create effective treatments that enhance patient outcomes in critical health issues.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

General Fusion Inc., established in 2002 and headquartered in Burnaby, Canada, specializes in developing commercial Magnetized Target Fusion (MTF), a hybrid fusion method combining magnetic confinement and inertial confinement principles. The company focuses on creating utility-scale fusion power using its patent-pending MTF concept, which has the potential to provide clean, safe, and economical energy. General Fusion develops key subsystems such as plasma injectors, acoustic drivers, and liquid metal vortex compression tests to advance its MTF technology. Backed by a global syndicate of investors, industry leaders, and technology pioneers, General Fusion aims to demonstrate and commercialize its innovative fusion power plants by the end of the decade.

D3O is an innovative company specializing in impact protection solutions through its patented smart materials. The company's technology, which utilizes non-Newtonian fluids, enables the creation of shock-absorbing products that are applicable across various sectors, including motorcycle, sports, footwear, electronics, military, and workwear. D3O gained recognition during the 2006 Winter Olympics when its soft armor technology was adopted by the US and Canadian ski teams, revolutionizing the protective wear market. Their products are characterized by low profile, lightweight, flexible, and breathable designs that do not compromise on protection. D3O continues to lead the field of impact protection, providing pioneering solutions that enhance safety for soldiers, professional athletes, and industrial workers.

Exosect Limited is a technology company based in Winchester, United Kingdom, founded in 1999 as a spin-out from the University of Southampton. The company specializes in developing innovative delivery platforms that enhance the effectiveness of pesticide formulations, addressing challenges such as pest resistance, regulatory compliance, and food chain residues. Its primary offerings include the Entostat delivery platform, which utilizes an electrostatically charged micro powder for microencapsulation and targeted release of active ingredients, and the Entomag delivery platform, a ferrous micro powder designed for the precise delivery of synthetic chemicals to control crawling insects, particularly in public health applications. With a strong portfolio of 41 patents and 28 national product registrations, Exosect is well-equipped to commercialize its patented technologies across agriculture, public health, and animal health sectors, contributing to the protection of food from pests and diseases.

Rakuten Fits Me is a provider of innovative fit recommendation solutions tailored for eCommerce fashion retailers, focusing on enhancing the online shopping experience by prioritizing fit and body shapes. The company utilizes a combination of garment data and shopper-specific measurements, derived from factors such as height, weight, age, and body shape, to accurately recommend the best-fitting sizes for customers. By leveraging deep statistical analysis of extensive body scan data, Rakuten Fits Me enables its data scientists to infer precise measurements that align with individual shopper profiles. Each garment is meticulously analyzed by garment technologists, who consider various elements, including silhouette and stretch, to inform fit preferences. This personalized approach helps shoppers make informed decisions, ensuring they select clothing that fits well and meets their style expectations. Ultimately, Rakuten Fits Me stands out as a unique size and fit solution provider, aligning product data with shopper body data to deliver an optimal fit experience consistently.

SmartKem Limited is a Manchester-based company that specializes in the development and marketing of organic semiconductors aimed at enhancing the manufacturing of liquid crystal and organic light-emitting diode displays. Founded in 2008, SmartKem focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors, specifically its patented truFLEX inks. These inks are applied on low-cost substrates to create organic thin-film transistor circuits, which are essential for a range of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company generates revenue through the sale of truFLEX inks and demonstration products, positioning itself at the forefront of semiconductor innovation for next-generation electronic devices.

OptiNose, Inc., established in 2010 and headquartered in Yardley, Pennsylvania, is a specialty pharmaceutical company specializing in nasal drug delivery technologies and therapies. The company's proprietary Bi-Directional Delivery system enables more efficient drug deposition in the upper posterior regions of the nasal cavity, unlike traditional devices. OptiNose's flagship product, XHANCE, utilizes this technology to deliver a topically-acting corticosteroid for treating chronic rhinosinusitis with and without nasal polyps. The company is also developing OPN-300 for rare genetic obesity and autism spectrum disorder treatments, and has licensing agreements for Onzetra Xsail and orexin receptor-related products. OptiNose has offices in Norway and the UK, focusing on improving drug delivery, onset of action, efficacy, and reducing side effects.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Xeros Technology Group plc specializes in developing and commercializing polymer-based technologies aimed at reducing water usage in cleaning processes across various sectors, including fabric and garment manufacturing, as well as industrial and domestic laundry. The company has created innovative products such as XOrbs, which utilize polymer technology to effectively remove dirt and stains with minimal water, and XDrum, designed for fabric and garment manufacturing applications. Additionally, it offers XFiltra, a system that facilitates the easy disposal of collected fibers by de-watering filtered materials. Originating from research by Professor Stephen Burkinshaw at the University of Leeds, Xeros's patented polymer bead cleaning system demonstrates significant potential for cost savings and environmental benefits in commercial laundry and other industries like leather processing and metal cleaning. Based in Rotherham, United Kingdom, Xeros continues to expand its operations in Europe and North America.

Trusted Insight is an online investment network that connects institutional investors with curated information and resources related to alternative assets. Established in 2010 by Alex Bangash, the platform boasts over 140,000 members who manage more than $18 trillion in assets, with approximately 30,000 institutional investors interacting with the network weekly. Trusted Insight offers a range of services, including news updates, job listings, rankings, and both online and offline events, creating a forum for investment professionals to share insights and stay informed about trends in private equity, hedge funds, real estate, and private companies. With offices in New York City and San Francisco, Trusted Insight has become a rapidly growing and trusted source for alternative investment information.

General Fusion Inc., established in 2002 and headquartered in Burnaby, Canada, specializes in developing commercial Magnetized Target Fusion (MTF), a hybrid fusion method combining magnetic confinement and inertial confinement principles. The company focuses on creating utility-scale fusion power using its patent-pending MTF concept, which has the potential to provide clean, safe, and economical energy. General Fusion develops key subsystems such as plasma injectors, acoustic drivers, and liquid metal vortex compression tests to advance its MTF technology. Backed by a global syndicate of investors, industry leaders, and technology pioneers, General Fusion aims to demonstrate and commercialize its innovative fusion power plants by the end of the decade.

Vasopharm GmbH is a biopharmaceutical company based in Wurzburg, Germany, specializing in the discovery and development of therapeutics for cerebro- and cardiovascular diseases. Founded in 1998, Vasopharm focuses on addressing acute niche indications with significant unmet medical needs. The company's therapeutic pipeline features VAS203, an allosteric nitric oxide synthase inhibitor designed to reduce excessive nitric oxide production in cerebral vessels, thereby preventing dangerous increases in intracranial pressure and mitigating inflammatory responses following traumatic brain injury. Additionally, Vasopharm is developing VAS2870, a modulator of NAD(P)H oxidase, aimed at treating peripheral arterial occlusive diseases. Through its innovative approaches, Vasopharm seeks to create effective treatments that enhance patient outcomes in critical health issues.

NewMotion is a leading provider of advanced charging solutions for electric vehicle (EV) drivers, focusing on facilitating the use of renewable energy sources for charging. With over 12,000 connected charge points, NewMotion boasts one of the largest and fastest-growing charging networks in Europe, catering to a significant portion of EV drivers in the Netherlands. The company simplifies electric driving by offering a charge card that grants access to numerous charging locations, ensuring convenience for users. In addition to serving individual drivers, NewMotion collaborates with leasing companies and car manufacturers to provide charging solutions for businesses. The company is actively expanding its network across the Netherlands, Belgium, Germany, and Norway, reinforcing its commitment to promoting electric mobility and sustainable energy usage.

Exosect Limited is a technology company based in Winchester, United Kingdom, founded in 1999 as a spin-out from the University of Southampton. The company specializes in developing innovative delivery platforms that enhance the effectiveness of pesticide formulations, addressing challenges such as pest resistance, regulatory compliance, and food chain residues. Its primary offerings include the Entostat delivery platform, which utilizes an electrostatically charged micro powder for microencapsulation and targeted release of active ingredients, and the Entomag delivery platform, a ferrous micro powder designed for the precise delivery of synthetic chemicals to control crawling insects, particularly in public health applications. With a strong portfolio of 41 patents and 28 national product registrations, Exosect is well-equipped to commercialize its patented technologies across agriculture, public health, and animal health sectors, contributing to the protection of food from pests and diseases.

Rakuten Fits Me is a provider of innovative fit recommendation solutions tailored for eCommerce fashion retailers, focusing on enhancing the online shopping experience by prioritizing fit and body shapes. The company utilizes a combination of garment data and shopper-specific measurements, derived from factors such as height, weight, age, and body shape, to accurately recommend the best-fitting sizes for customers. By leveraging deep statistical analysis of extensive body scan data, Rakuten Fits Me enables its data scientists to infer precise measurements that align with individual shopper profiles. Each garment is meticulously analyzed by garment technologists, who consider various elements, including silhouette and stretch, to inform fit preferences. This personalized approach helps shoppers make informed decisions, ensuring they select clothing that fits well and meets their style expectations. Ultimately, Rakuten Fits Me stands out as a unique size and fit solution provider, aligning product data with shopper body data to deliver an optimal fit experience consistently.

Xeros Technology Group plc specializes in developing and commercializing polymer-based technologies aimed at reducing water usage in cleaning processes across various sectors, including fabric and garment manufacturing, as well as industrial and domestic laundry. The company has created innovative products such as XOrbs, which utilize polymer technology to effectively remove dirt and stains with minimal water, and XDrum, designed for fabric and garment manufacturing applications. Additionally, it offers XFiltra, a system that facilitates the easy disposal of collected fibers by de-watering filtered materials. Originating from research by Professor Stephen Burkinshaw at the University of Leeds, Xeros's patented polymer bead cleaning system demonstrates significant potential for cost savings and environmental benefits in commercial laundry and other industries like leather processing and metal cleaning. Based in Rotherham, United Kingdom, Xeros continues to expand its operations in Europe and North America.

Realeyes is a pioneering company specializing in computer vision and emotion AI. It helps businesses enhance customer experiences and drive growth by measuring human responses to video content at scale and speed. Using webcams and advanced machine learning techniques, Realeyes' platform analyzes facial expressions to quantify emotional reactions, enabling clients like Mars Inc., P&G, and Netflix to create targeted, optimized content. Over 200 leading brands and media companies rely on Realeyes for these insights.

Exosect Limited is a technology company based in Winchester, United Kingdom, founded in 1999 as a spin-out from the University of Southampton. The company specializes in developing innovative delivery platforms that enhance the effectiveness of pesticide formulations, addressing challenges such as pest resistance, regulatory compliance, and food chain residues. Its primary offerings include the Entostat delivery platform, which utilizes an electrostatically charged micro powder for microencapsulation and targeted release of active ingredients, and the Entomag delivery platform, a ferrous micro powder designed for the precise delivery of synthetic chemicals to control crawling insects, particularly in public health applications. With a strong portfolio of 41 patents and 28 national product registrations, Exosect is well-equipped to commercialize its patented technologies across agriculture, public health, and animal health sectors, contributing to the protection of food from pests and diseases.

Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled respiratory medicines for conditions such as asthma and chronic obstructive pulmonary disease. Established in 2006, Prosonix specializes in generic mono and combination therapies that utilize inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. The company employs proprietary ultrasonic particle engineering technologies to create and optimize drug formulations, enhancing the delivery and effectiveness of its inhaled medications. Prosonix is recognized for its innovative approach to developing new methods for transforming molecules into particles suitable for inhalation, allowing for tailored therapeutic solutions. As of June 2015, Prosonix operates as a subsidiary of Circassia Limited.

Rakuten Fits Me is a provider of innovative fit recommendation solutions tailored for eCommerce fashion retailers, focusing on enhancing the online shopping experience by prioritizing fit and body shapes. The company utilizes a combination of garment data and shopper-specific measurements, derived from factors such as height, weight, age, and body shape, to accurately recommend the best-fitting sizes for customers. By leveraging deep statistical analysis of extensive body scan data, Rakuten Fits Me enables its data scientists to infer precise measurements that align with individual shopper profiles. Each garment is meticulously analyzed by garment technologists, who consider various elements, including silhouette and stretch, to inform fit preferences. This personalized approach helps shoppers make informed decisions, ensuring they select clothing that fits well and meets their style expectations. Ultimately, Rakuten Fits Me stands out as a unique size and fit solution provider, aligning product data with shopper body data to deliver an optimal fit experience consistently.

NewMotion is a leading provider of advanced charging solutions for electric vehicle (EV) drivers, focusing on facilitating the use of renewable energy sources for charging. With over 12,000 connected charge points, NewMotion boasts one of the largest and fastest-growing charging networks in Europe, catering to a significant portion of EV drivers in the Netherlands. The company simplifies electric driving by offering a charge card that grants access to numerous charging locations, ensuring convenience for users. In addition to serving individual drivers, NewMotion collaborates with leasing companies and car manufacturers to provide charging solutions for businesses. The company is actively expanding its network across the Netherlands, Belgium, Germany, and Norway, reinforcing its commitment to promoting electric mobility and sustainable energy usage.

SOASTA, Inc. is a performance analytics platform that specializes in cloud testing and monitoring solutions for web and mobile applications. Founded in 2006 and headquartered in Mountain View, California, the company provides comprehensive tools that help digital businesses analyze and optimize their performance in real-time. Its offerings include mPulse, a real user monitoring solution that correlates performance with business outcomes; CloudTest, a platform for load and performance testing; TouchTest, which focuses on mobile functional test automation; and the Digital Operations Center, which delivers insights into performance metrics. SOASTA has conducted over 10 million tests and measured more than 100 billion user experiences, serving a range of industry-leading clients. The company also offers a variety of support services, including testing consultation, training, and development assistance, ensuring that clients can effectively manage their digital performance strategies. As of 2017, SOASTA operates as a subsidiary of Akamai Technologies.

CYTOO SA is a life sciences company based in Grenoble, France, specializing in micropattern-enhanced cell-based assays aimed at improving cellular analysis for the research community. Founded in 2008, the company develops, manufactures, and commercializes innovative technologies, including CYTOO chips and CYTOOplates, which utilize glass coverslips and microplates featuring adhesive micropatterns for various applications such as immunofluorescence assays and high-resolution live microscopy. Their products are designed to enhance the physiological relevance of cellular models, thereby reducing variability and increasing the reliability of assay results. CYTOO's technologies facilitate studies in areas such as cell shape, cytoskeleton organization, cell polarity, and quantitative cell phenotyping, catering to a diverse range of research goals. In addition to their product offerings, CYTOO provides assay development services to further support researchers in their experimental endeavors.

Exosect Limited is a technology company based in Winchester, United Kingdom, founded in 1999 as a spin-out from the University of Southampton. The company specializes in developing innovative delivery platforms that enhance the effectiveness of pesticide formulations, addressing challenges such as pest resistance, regulatory compliance, and food chain residues. Its primary offerings include the Entostat delivery platform, which utilizes an electrostatically charged micro powder for microencapsulation and targeted release of active ingredients, and the Entomag delivery platform, a ferrous micro powder designed for the precise delivery of synthetic chemicals to control crawling insects, particularly in public health applications. With a strong portfolio of 41 patents and 28 national product registrations, Exosect is well-equipped to commercialize its patented technologies across agriculture, public health, and animal health sectors, contributing to the protection of food from pests and diseases.

Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled respiratory medicines for conditions such as asthma and chronic obstructive pulmonary disease. Established in 2006, Prosonix specializes in generic mono and combination therapies that utilize inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. The company employs proprietary ultrasonic particle engineering technologies to create and optimize drug formulations, enhancing the delivery and effectiveness of its inhaled medications. Prosonix is recognized for its innovative approach to developing new methods for transforming molecules into particles suitable for inhalation, allowing for tailored therapeutic solutions. As of June 2015, Prosonix operates as a subsidiary of Circassia Limited.

General Fusion Inc., established in 2002 and headquartered in Burnaby, Canada, specializes in developing commercial Magnetized Target Fusion (MTF), a hybrid fusion method combining magnetic confinement and inertial confinement principles. The company focuses on creating utility-scale fusion power using its patent-pending MTF concept, which has the potential to provide clean, safe, and economical energy. General Fusion develops key subsystems such as plasma injectors, acoustic drivers, and liquid metal vortex compression tests to advance its MTF technology. Backed by a global syndicate of investors, industry leaders, and technology pioneers, General Fusion aims to demonstrate and commercialize its innovative fusion power plants by the end of the decade.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Accept helps companies increase the speed and certainty of new product success and turn product innovation into a competitive advantage. Accept SaaS innovation management solutions help companies engage communities, prioritize and manage new ideas, align products with company strategy, and unify execution across teams.

Xeros Technology Group plc specializes in developing and commercializing polymer-based technologies aimed at reducing water usage in cleaning processes across various sectors, including fabric and garment manufacturing, as well as industrial and domestic laundry. The company has created innovative products such as XOrbs, which utilize polymer technology to effectively remove dirt and stains with minimal water, and XDrum, designed for fabric and garment manufacturing applications. Additionally, it offers XFiltra, a system that facilitates the easy disposal of collected fibers by de-watering filtered materials. Originating from research by Professor Stephen Burkinshaw at the University of Leeds, Xeros's patented polymer bead cleaning system demonstrates significant potential for cost savings and environmental benefits in commercial laundry and other industries like leather processing and metal cleaning. Based in Rotherham, United Kingdom, Xeros continues to expand its operations in Europe and North America.

Exosect Limited is a technology company based in Winchester, United Kingdom, founded in 1999 as a spin-out from the University of Southampton. The company specializes in developing innovative delivery platforms that enhance the effectiveness of pesticide formulations, addressing challenges such as pest resistance, regulatory compliance, and food chain residues. Its primary offerings include the Entostat delivery platform, which utilizes an electrostatically charged micro powder for microencapsulation and targeted release of active ingredients, and the Entomag delivery platform, a ferrous micro powder designed for the precise delivery of synthetic chemicals to control crawling insects, particularly in public health applications. With a strong portfolio of 41 patents and 28 national product registrations, Exosect is well-equipped to commercialize its patented technologies across agriculture, public health, and animal health sectors, contributing to the protection of food from pests and diseases.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

General Fusion Inc., established in 2002 and headquartered in Burnaby, Canada, specializes in developing commercial Magnetized Target Fusion (MTF), a hybrid fusion method combining magnetic confinement and inertial confinement principles. The company focuses on creating utility-scale fusion power using its patent-pending MTF concept, which has the potential to provide clean, safe, and economical energy. General Fusion develops key subsystems such as plasma injectors, acoustic drivers, and liquid metal vortex compression tests to advance its MTF technology. Backed by a global syndicate of investors, industry leaders, and technology pioneers, General Fusion aims to demonstrate and commercialize its innovative fusion power plants by the end of the decade.

Inge Watertechnologies specializes in the development of ultrafiltration technology for water treatment applications. The company's innovative membrane separation process employs ultra-small pore filters that effectively remove particles, suspended solids, and microorganisms, including bacteria and viruses. This technology is designed to provide smart, safe, and reliable solutions for treating various types of water, including drinking, processed, sea, and wastewater. By ensuring the purification of water, Inge Watertechnologies delivers a dependable source of clean water for its clients.

Exosect Limited is a technology company based in Winchester, United Kingdom, founded in 1999 as a spin-out from the University of Southampton. The company specializes in developing innovative delivery platforms that enhance the effectiveness of pesticide formulations, addressing challenges such as pest resistance, regulatory compliance, and food chain residues. Its primary offerings include the Entostat delivery platform, which utilizes an electrostatically charged micro powder for microencapsulation and targeted release of active ingredients, and the Entomag delivery platform, a ferrous micro powder designed for the precise delivery of synthetic chemicals to control crawling insects, particularly in public health applications. With a strong portfolio of 41 patents and 28 national product registrations, Exosect is well-equipped to commercialize its patented technologies across agriculture, public health, and animal health sectors, contributing to the protection of food from pests and diseases.

VAIREX International Limited is a privately held company that specializes in the design, manufacture, and supply of air management systems tailored for hydrogen fuel cell and diesel emissions control markets. The company's products include advanced air systems featuring restrained vane compressors and regenerative blowers, which integrate motors and controllers to ensure efficient delivery of clean air for various applications. VAIREX serves a diverse clientele, including prominent original equipment manufacturers and Tier One suppliers in the fuel cell and diesel sectors across Europe, Asia, and North America. Established in 2007, VAIREX is headquartered in Cambridge, United Kingdom, with additional offices in Boulder, Colorado, and Tokyo, Japan.

Exosect Limited is a technology company based in Winchester, United Kingdom, founded in 1999 as a spin-out from the University of Southampton. The company specializes in developing innovative delivery platforms that enhance the effectiveness of pesticide formulations, addressing challenges such as pest resistance, regulatory compliance, and food chain residues. Its primary offerings include the Entostat delivery platform, which utilizes an electrostatically charged micro powder for microencapsulation and targeted release of active ingredients, and the Entomag delivery platform, a ferrous micro powder designed for the precise delivery of synthetic chemicals to control crawling insects, particularly in public health applications. With a strong portfolio of 41 patents and 28 national product registrations, Exosect is well-equipped to commercialize its patented technologies across agriculture, public health, and animal health sectors, contributing to the protection of food from pests and diseases.

iPolicy Networks is the developer of the world's first Intrusion Prevention Firewall delivering real-time, consistent security enforcement for enterprises, carriers and managed security service providers. The iPolicy Intrusion Prevention Firewall supports multiple security functions built on iPolicy's Single Pass Architecture(TM) that enables superior performance even under heavy traffic load.

t2cure GmbH is a biopharmaceutical company based in Frankfurt am Main, Germany, founded in 2006. The company specializes in developing progenitor cell-based regenerative therapeutics aimed at treating cardiovascular diseases, including ischemic heart diseases, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy. t2cure focuses on utilizing autologous bone marrow-derived progenitor cells, which have the potential to initiate tissue repair by enhancing blood flow and releasing substances that promote cell regeneration. This innovative approach aims to provide new treatment options for patients suffering from conditions such as myocardial infarction and peripheral vascular diseases, facilitating quicker recovery and improved health outcomes.

iPolicy Networks is the developer of the world's first Intrusion Prevention Firewall delivering real-time, consistent security enforcement for enterprises, carriers and managed security service providers. The iPolicy Intrusion Prevention Firewall supports multiple security functions built on iPolicy's Single Pass Architecture(TM) that enables superior performance even under heavy traffic load.

MBlox, established in 1999, is a pioneering global mobile messaging company. It maintains over 100 direct carrier relationships and is renowned for its expertise in SMS services. The company's cloud-based platform processes 7 billion mobile messages annually for more than 4,000 clients, ranging from start-ups to multinational corporations. MBlox offers 24/7 email support and customizable support packages to cater to diverse business needs. Its services span various sectors, including financial services, government, transportation, retail, and advertising.